Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Lam, 2006, Secondary hormonal therapy for advanced prostate cancer, J Urol, 175, 27, 10.1016/S0022-5347(05)00034-0 Crawford, 2009, Understanding the epidemiology, natural history, and key pathways involved in prostate cancer, Urology, 73, S4, 10.1016/j.urology.2009.03.001 Crawford, 1989, A controlled trial of leuprolide with and without flutamide in prostatic carcinoma, N Engl J Med, 321, 419, 10.1056/NEJM198908173210702 Eisenberger, 1998, Bilateral orchiectomy with or without flutamide for metastatic prostate cancer, N Engl J Med, 339, 1036, 10.1056/NEJM199810083391504 Scher, 2005, Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis, J Clin Oncol, 23, 8253, 10.1200/JCO.2005.03.4777 Titus, 2005, Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer, Clin Cancer Res, 11, 4653, 10.1158/1078-0432.CCR-05-0525 Attar, 2009, Castration-resistant prostate cancer: locking up the molecular escape routes, Clin Cancer Res, 15, 3251, 10.1158/1078-0432.CCR-08-1171 Mohler, 2004, The androgen axis in recurrent prostate cancer, Clin Cancer Res, 10, 440, 10.1158/1078-0432.CCR-1146-03 Massard, 2011, Targeting continued androgen receptor signaling in prostate cancer, Clin Cancer Res, 17, 3876, 10.1158/1078-0432.CCR-10-2815 Tannock, 2004, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer, N Engl J Med, 351, 1502, 10.1056/NEJMoa040720 Petrylak, 2004, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, 351, 1513, 10.1056/NEJMoa041318 Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X O'Donnell, 2004, Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer, Br J Cancer, 90, 2317, 10.1038/sj.bjc.6601879 Barrie, 1994, Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase), J Steroid Biochem Mol Biol, 50, 267, 10.1016/0960-0760(94)90131-7 Attard, 2009, Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer, J Clin Oncol, 27, 3742, 10.1200/JCO.2008.20.0642 Danila, 2010, Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer, J Clin Oncol, 28, 1496, 10.1200/JCO.2009.25.9259 Reid, 2010, Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate, J Clin Oncol, 28, 1489, 10.1200/JCO.2009.24.6819 Ryan, 2010, Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy, J Clin Oncol, 28, 1481, 10.1200/JCO.2009.24.1281 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N Engl J Med, 364, 1995, 10.1056/NEJMoa1014618 Bubley, 1999, Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group, J Clin Oncol, 17, 3461, 10.1200/JCO.1999.17.11.3461 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Thuret, 2008, The postchemotherapy PSA surge syndrome, Ann Oncol, 19, 1308, 10.1093/annonc/mdn062 Berthold, 2008, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study, J Clin Oncol, 26, 242, 10.1200/JCO.2007.12.4008 Fizazi, 2007, Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data, Lancet Oncol, 8, 994, 10.1016/S1470-2045(07)70284-X Saad, 2002, A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma, J Natl Cancer Inst, 94, 1458, 10.1093/jnci/94.19.1458 Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 Sartor, 2012, Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA), Proc Am Soc Clin Oncol, 30 Italiano, 2009, Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer, Eur Urol, 55, 1368, 10.1016/j.eururo.2008.07.078 Scher, 2010, Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study, Lancet, 375, 1437, 10.1016/S0140-6736(10)60172-9 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 10.1056/NEJMoa1207506 Scher, 2011, Proc Am Soc Clin Oncol, 29 Ryan CJ, Peng W, Kheoh T, et al. Association of reduction in serum androgens and change in serum PSA in patients treated with abiraterone acetate (AA): a subset analysis of the COU-AA-301 phase 3 randomized trial. American Association for Cancer Research (AACR) Annual Meeting, March 31–April 4, 2012, Chicago, IL, USA; abstr 3635. Harland S, de Bono JS, Haqq C, et al. Abiraterone acetate improves functional status in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel: results from the COU-AA-301 phase 3 study. European Multidisciplinary Cancer Congress, Sept 23–27, 2011, Stockholm, Sweden; abstr 7.001. Logothetis, 2011, Effect of abiraterone acetate on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer post docetaxel: results from the COU-AA-301 Phase 3 Study, Proc Am Soc Clin Oncol, 29 Sternberg CN, Scher HI, Molina A, et al. Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer post-docetaxel: results from the COU-AA-301 phase 3 study. European Multidisciplinary Cancer Congress, Sept 23–27, 2011, Stockholm, Sweden; abstr 7.015. Ryan, 2012, Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC), Proc Am Soc Clin Oncol, 30